Paroxysmal Supraventricular Tachycardia Market Research Report – Forecast to 2027

Paroxysmal Supraventricular Tachycardia (PSVT) Market: by Type (AVNRT, AVRT, PAT, WPW) Diagnosis (EPS, Echocardiogram, Holter Monitor, Event Monitor) Treatment (Physical Maneuvers, medications), End-User (Hospitals & Clinics) - Forecast Till 2027

ID: MRFR/MED/4462-HCR | February 2021 | Region: Global | 100 pages

Paroxysmal Supraventricular Tachycardia (PSVT) Market Scenario


Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.


The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.


The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.


The Paroxysmal Supraventricular Tachycardia (PSVT) market is expected to register a CAGR of approximately 6.50% during the forecast period, 2017–2023.


Intended Audience



  • Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers

  • Paroxysmal Supraventricular Tachycardia Treatment Providers

  • Imaging Device Manufacturers

  • Hospitals and Clinics

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities

  • Market Research and Consulting Service Providers

  • Potential Investors


Figure 1: Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, by Region


 Paroxysmal Supraventricular Tachycardia (PSVT) Market


Segmentation


The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).


On the basis of diagnosis, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.


On the basis of treatment, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.


On the basis of end-user, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.


Research Methodology


 Paroxysmal Supraventricular Tachycardia (PSVT) Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis


The Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.


Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.


The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of paroxysmal supraventricular tachycardia market.


Key Players


Some of the key players in the Paroxysmal Supraventricular Tachycardia (PSVT) market are GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.50% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End-user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing demand for diagnostic outpatient surgeries
  • Increasing healthcare services
  • Availability of low cost of labor
  • Increasing number of hospitals, and better access to technology


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heartbeats.

    Paroxysmal Supraventricular Tachycardia Market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2017 to 2023.

    Growing prevalence of cardiovascular diseases is the major driver for the Paroxysmal Supraventricular Tachycardia Market.

    The Americas dominate the global Paroxysmal Supraventricular Tachycardia Market.

    Leading players in the Paroxysmal Supraventricular Tachycardia Market include GSK, Novartis, and Pfizer, among others.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope Of The Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power Of Suppliers

    5.1.2 Bargaining Power Of Buyers

    5.1.3 Threat Of New Entrants

    5.1.4 Threat Of Substitutes

    5.1.5 Intensity Of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type

    6.1 Introduction

    6.2 AV Nodal Re-Entrant Tachycardia (AVNRT)

    6.2.1 Market Estimates & Forecast, 2020–2027

    6.3 AV Reciprocating Tachycardia (AVRT),

    6.3.1 Market Estimates & Forecast, 2020–2027

    6.4 Paroxysmal Atrial Tachycardia (PAT),

    6.4.1 Market Estimates & Forecast, 2020–2027

    6.5 Wolff-Parkinson-White Syndrome (WPW)

    6.5.1 Market Estimates & Forecast, 2020–2027

    Chapter 7. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis

    7.1 Introduction

    7.2 Electrophysiology Study (EPS)

    7.2.1 Market Estimates & Forecast, 2020–2027

    7.3 Stress Test

    7.3.1 Market Estimates & Forecast, 2020–2027

    7.4 Cardiac Catheterization

    7.4.1 Market Estimates & Forecast, 2020–2027

    7.5 Coronary Angiography

    7.5.1 Market Estimates & Forecast, 2020–2027

    7.6 Electrocardiogram (ECG)

    7.6.1 Market Estimates & Forecast, 2020–2027

    7.7 Echocardiogram

    7.7.1 Market Estimates & Forecast, 2020–2027

    7.8 Holter Monitor

    7.8.1 Market Estimates & Forecast, 2020–2027

    7.9 Event Monitor

    7.9.1 Market Estimates & Forecast, 2020–2027

    7.10 Implantable Monitor

    7.10.1 Market Estimates & Forecast, 2020–2027

    7.11 Lab Tests

    7.11.1 Market Estimates & Forecast, 2020–2027

    7.11.2 Blood Test

    7.11.2.1 Market Estimates & Forecast, 2020–2027

    7.11.3 Urine Test

    7.11.3.1 Market Estimates & Forecast, 2020–2027

    7.11.4 Others

    7.12 Others

    Chapter 8. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment

    8.1 Introduction

    8.2 Physical Maneuvers

    8.2.1 Market Estimates & Forecast, 2020–2027

    8.3 Medications

    8.3.1 Market Estimates & Forecast, 2020–2027

    8.3.2 Calcium Channel Blockers

    8.3.2.1 Market Estimates & Forecast, 2020–2027

    8.3.2.2 Diltiazem

    8.3.2.2.1 Market Estimates & Forecast, 2020–2027

    8.3.2.3 Verapamil

    8.3.2.3.1 Market Estimates & Forecast, 2020–2027

    8.3.2.4 Others

    8.3.2.4.1 Market Estimates & Forecast, 2020–2027

    8.3.2.5 Diltiazem

    8.3.2.5.1 Market Estimates & Forecast, 2020–2027

    8.3.3 Antiarrhythmic Medication

    8.3.3.1 Market Estimates & Forecast, 2020–2027

    8.3.3.2 Sotalol

    8.3.3.2.1 Market Estimates & Forecast, 2020–2027

    8.3.3.3 Amiodarone

    8.3.3.3.1 Market Estimates & Forecast, 2020–2027

    8.3.3.4 Amiodarone

    8.3.3.4.1 Market Estimates & Forecast, 2020–2027

    8.3.3.5 Flecainide

    8.3.3.5.1 Market Estimates & Forecast, 2020–2027

    8.3.3.6 Propafenone

    8.3.3.6.1 Market Estimates & Forecast, 2020–2027

    8.3.3.7 Adenosine

    8.3.3.7.1 Market Estimates & Forecast, 2020–2027

    8.3.4 Beta Blockers

    8.3.4.1 Market Estimates & Forecast, 2020–2027

    8.3.5 Others

    8.4 Catheter Ablation

    8.4.1 Market Estimates & Forecast, 2020–2027

    8.5 Pacemaker

    8.5.1 Market Estimates & Forecast, 2020–2027

    8.6 Cardioversion

    8.6.1 Market Estimates & Forecast, 2020–2027

    Chapter 9. Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By End-User

    9.1 Introduction

    9.2 Hospitals & Clinics

    9.2.1 Market Estimates & Forecast, 2020–2027

    9.3 Diagnostic Centers

    9.3.1 Market Estimates & Forecast, 2020–2027

    9.4 Medical Research Centers

    9.4.1 Market Estimates & Forecast, 2020–2027

    9.5 Others

    Chapter .10 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K.

    10.3.1.6 Rest Of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic Of Korea

    10.4.6 Rest Of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest Of The Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12 Company Profiles

    12.1 GlaxoSmithKline PLC

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Sanofi SA

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Pfizer Inc.

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Novartis International AG

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Teva Pharmaceutical Industries Ltd.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.6 Medtronic, Inc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Glenmark Pharmaceuticals

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 St. Jude Medical, Inc.

    12.8.1 Company Overview

    12.8.2 Product/Business Segment Overview

    12.8.3 Financial Overview

    12.8.4 Key Development

    12.8.5 SWOT Analysis

    12.9 Boston Scientific Corporation

    12.9.1 Company Overview

    12.9.2 Product Overview

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.10 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs Of The Market

    13.2 Key Companies To Watch

    13.3 Prediction Of The Pharmaceutical Industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Paroxysmal Supraventricular Tachycardia (PSVT) Industry Synopsis, 2020–2027

    Table 2 Paroxysmal Supraventricular Tachycardia (PSVT) Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Region, 2020–2027, (USD Million)

    Table 4 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 5 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 6 Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 7 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 8 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 9 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 10 U.S. Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 11 U.S. Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 12 U.S. Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 13 Canada Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 14 Canada Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 15 Canada Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 16 South America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 17 South America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 18 South America Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 19 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 20 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 21 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 22 Western Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 23 Western Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 24 Western Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 25 Eastern Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 26 Eastern Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 27 Eastern Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 28 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 29 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 30 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    Table 31 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Type, 2020–2027, (USD Million)

    Table 32 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Diagnosis, 2020–2027, (USD Million)

    Table 33 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market, By Treatment, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation For Paroxysmal Supraventricular Tachycardia (PSVT) Market

    Figure 3 Segmentation Market Dynamics For Paroxysmal Supraventricular Tachycardia (PSVT) Market

    Figure 4 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Type 2020

    Figure 5 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Diagnosis 2020

    Figure 6 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Treatment, 2020

    Figure 7 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Region, 2020

    Figure 8 North America Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2020

    Figure 9 Europe Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2020

    Figure 10 Asia Pacific Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2020

    Figure 11 Middle East & Africa Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, By Country, 2020

    Figure 12 Global Paroxysmal Supraventricular Tachycardia (PSVT) Market: Company Share Analysis, 2020 (%)

    Figure 13 GLAXOSMITHKLINE PLC: Key Financials

    Figure 14 GLAXOSMITHKLINE PLC: Segmental Revenue

    Figure 15 GLAXOSMITHKLINE PLC: Geographical Revenue

    Figure 16 Sanofi SA: Key Financials

    Figure 17 Sanofi SA: Segmental Revenue

    Figure 18 Sanofi SA: Geographical Revenue

    Figure 19 Pfizer Inc.: Key Financials

    Figure 20 Pfizer Inc.: Segmental Revenue

    Figure 21 Pfizer Inc.: Geographical Revenue

    Figure 22 Novartis International AG: Key Financials

    Figure 23 Novartis International AG: Segmental Revenue

    Figure 24 Novartis International AG: Geographical Revenue

    Figure 25 Teva Pharmaceutical Industries Ltd.: Key Financials

    Figure 26 Teva Pharmaceutical Industries Ltd.: Segmental Revenue

    Figure 27 Teva Pharmaceutical Industries Ltd.: Geographical Revenue

    Figure 28 Medtronic, Inc..: Key Financials

    Figure 29 Medtronic, Inc.: Segmental Revenue

    Figure 30 Medtronic, Inc.: Geographical Revenue

    Figure 31 Glenmark Pharmaceuticals: Key Financials

    Figure 32 Glenmark Pharmaceuticals: Segmental Revenue

    Figure 33 Glenmark Pharmaceuticals: Geographical Revenue

    Figure 34 St. Jude Medical, Inc.: Key Financials

    Figure 35 St. Jude Medical, Inc.: Segmental Revenue

    Figure 36 St. Jude Medical, Inc.: Geographical Revenue

    Figure 37 Boston Scientific Corporation: Key Financials

    Figure 38 Boston Scientific Corporation: Segmental Revenue

    Figure 39 Boston Scientific Corporation: Geographical Revenue